Description: Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
Home Page: opthea.com
650 Chapel Street
South Yarra,
VIC
3141
Australia
Phone:
61 3 9826 0399
Officers
| Name | Title |
|---|---|
| Dr. Frederic Guerard M.S., Pharm.D. | Chief Executive Officer |
| Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. | Founder & Chief Innovation Officer |
| Ms. Karen Adams CPA | VP of Finance & Company Secretary |
| Mr. Thomas Charles Reilly | Chief Financial Officer |
| Mr. Kevin Bitter | VP of Strategy & Corporate Development |
| Mr. Anand Sundaram | Vice President Marketing |
| Dr. Fang Li Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Julie Clark M.D., M.S. | Senior Vice President of Clinical Development |
| Dr. Arshad M. Khanani M.A., M.D. | Chief Medical Advisor & Chairman of Medical Advisory Board |
| Ms. Jen Watts | VP Global Clinical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 6.5789 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.9188 |
| Price-to-Sales TTM: | 2027.6155 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 33 |